FOLLICULAR LYMPHOMA PATIENT‐DERIVED ORGANOIDS FOR BISPECIFIC T‐CELL ENGAGER IMMUNOTHERAPY.

We therefore developed a robust patient-derived lymphoma organoid (PDLO) system utilizing primary biopsies from FL patients and assessed response to bispecific T-cell mediated immunotherapy. Novel immunotherapies including bispecific T-cell engagers require an intact TME for immune effector function and cannot be modeled in traditional B-cell monocultures. B Conclusions: b FL PDLOs allow ex vivo modeling of T-cell mediated immunotherapies with B-cell killing, activated T-cell expansion, and T-cell exhaustion signatures. [Extracted from the article]